---
title: "HSBC Research Raises INNOVENT BIO  TP to HKD133 as Johnson & Johnson Acquires Overseas Pipeline Partner Ollin"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306250225.md"
description: "HSBC Research raised its target price for INNOVENT BIO to HKD133 from HKD130, maintaining a 'Buy' rating. This adjustment follows Johnson & Johnson's $3.325 billion acquisition of Ollin, a partner in INNOVENT's overseas pipeline. HSBC estimates INNOVENT holds an ~8% stake in Ollin and stands to gain double-digit royalties from the OLN324 antibody. Additionally, the broker upgraded revenue and profit forecasts for 2026-2028, citing strong domestic sales ramp-up and effective cost controls."
datetime: "2026-11-20T09:25:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306250225.md)
  - [en](https://longbridge.com/en/news/306250225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306250225.md)
generator: "portal-rs"
---

# HSBC Research Raises INNOVENT BIO  TP to HKD133 as Johnson & Johnson Acquires Overseas Pipeline Partner Ollin

HSBC Global Investment Research issued a research report stating that Johnson & Johnson recently announced the acquisition of Ollin for USD3.325 billion, including an upfront payment of USD2.2 billion and USD1.125 billion in regulatory and commercial milestone payments. Ollin is a partner of INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% . The broker maintained its "Buy" rating on INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% and raised its TP from HKD130 to HKD133.

INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% developed and licensed overseas rights of the VEGF/Ang2 bispecific antibody OLN324 to Ollin for global development. The project is currently undergoing global Phase III studies for eye diseases including diabetic macular edema (DME) and wet age-related macular degeneration (AMD). It marks INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% 's first out-licensing deal in ophthalmology with a multinational pharmaceutical company. HSBC Global Investment Research estimated that INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% holds about an 8% stake in Ollin and is entitled to a double-digit sales royalty, which could benefit the company and generate recurring income after OLN324 is launched overseas. If Phase III results replicate early-stage data, peak sales of OLN324 could reach USD5 billion.

The broker is also optimistic about the ramp-up in INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% 's domestic sales and raised its revenue forecasts for 2026 to 2028 by 2% to 3% to RMB19.8 billion, RMB24.8 billion and RMB29.9 billion, respectively. Among them, GLP-1 revenue is forecast at RMB2.7 billion, RMB4.7 billion and RMB5.4 billion, respectively. Meanwhile, due to effective cost controls, the broker also raised its net profit forecasts by 13% to 20%, expecting net profit to reach RMB2.4 billion, RMB3.6 billion and RMB5 billion, respectively. (gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-20 16:25.)

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)

## Related News & Research

- [UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO  Ophthalmology R&D](https://longbridge.com/en/news/305767362.md)
- [Johnson & Johnson To Acquire Ollin Biosciences And Late-Stage Bispecific Antibody With Best-In-Class Potential In Ophthalmology](https://longbridge.com/en/news/305681892.md)
- [Johnson & Johnson looking to buy Ollin Biosciences for up to $3.4 billion, FT says](https://longbridge.com/en/news/305587733.md)
- [J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences](https://longbridge.com/en/news/305707055.md)
- [Innovent adds seven products to China’s 2026 NRDL](https://longbridge.com/en/news/305580225.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**